BIOMIMESYS® Oncology is a relevant hydroscaffold for cancer-related in vitro studies

BIOMIMESYS® Oncology is mostly composed of hyaluronic acid (HA), biofunctionnalized with undenaturated collagen I. HA, by interacting with its binding proteins (CD44, RHAMM, ICAM-1), is an active participant in inflammatory, angiogenic, fibrotic and cancer-promoting processes (Figure 1). We are currently looking at the effect of different elastic moduli of BIOMIMESYS® Read more…

Veronique joins us as a PhD student to develop a new in vitro neurological model

Veronique obtained an engineering degree from the Toulouse agronomic school (ENSAT) in 2017, with a specialization in biotechnology at AgroParisTech. During her studies, she worked on the cholinergic receptors structure of the parasitic nematode Trichinella spiralis during a 3-month internship in the French Agency for Food, Environmental and Occupational Health Read more…

Drug discovery : Need of reliable IVIVE for pharmacodynamics and pharmacokinetics assessment

For ethical and cost-related reasons, use of animals for the assessment of mode of action, metabolism and/or toxicity of new drug candidates has been increasingly scrutinized in research and industrial applications. Physiologically based pharmacokinetic (PBPK2) modeling is the most potent in silico tool used for extrapolation of pharmacokinetic parameters to Read more…

Poster – In vitro dermocosmetology : high content analysis approach using human primary keratinocytes and fibroblasts

Cell biology is part of the R&D activity in dermocosmetology, as providers of active extracts or pure compounds have to demonstrate their efficacy and safety. At HCS Pharma, we are developing new dermocosmetology assays on relevant cellular models, like human primary keratinocytes and human primary fibroblasts, using our automated platform and high content analysis system.